Eli Lilly's $3.51 Billion Volume Slumps to 23rd in Market-Wide Ranking Amid FDA Delays and Mixed Sentiment

On October 2, 2025, Eli Lilly (LLY) reported a trading volume of $3.51 billion, a 57.3% decline from the previous day, ranking 23rd in market-wide volume. The stock closed down 0.67%, reflecting subdued investor activity amid mixed market sentiment.

Recent developments highlight regulatory scrutiny as the FDA delayed approval of Eli’s novel diabetes drug pending additional safety data. Analysts noted the delay could push commercialization to late 2026, potentially impacting near-term revenue projections. Concurrently, a partnership with a European biotech firm to expand manufacturing capacity for its GLP-1 portfolio was announced, signaling long-term operational resilience.

Market participants observed limited short-term catalysts, with earnings expectations tempered by recent underperformance in its oncology division. Institutional trading patterns showed reduced open interest in options contracts, suggesting diminished speculative positioning compared to prior quarters.

To run this back-test rigorously I need to know exactly which universe of stocks we should be ranking by volume each day. A few practical options include all U.S. listed stocks, the Russell 1000, the S&P 500, or a custom list. Our toolkit processes one security or a pre-defined universe file at a time. Once the universe is confirmed, I can extract daily volumes, select the top 500 each day, and execute a 1-day-holding back-test from January 1, 2022, through today.